Bausch Health's debt burden and potential bankruptcy risks are mitigated by the likely sale of Bausch + Lomb, which could fetch a premium price. Bausch + Lomb's stable business and the recent ...

This suit was surfaced by Law.com Radar, ALM's source for immediate alerting on just filed cases in state and federal courts.

Bausch + Lomb has a pretty solid balance sheet that hasn’t changed a lot in the last few quarters. Read why I remain bullish ...

Bausch + Lomb BLCO shares ended the last trading session 14.5% higher at $17.80. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session.

Bausch & Lomb (NYSE:BLCO) may be worth around $28 a share in a potential takeover after reports that the eye care company is ...

This week, the Federal Reserve's decision to reduce interest rates by 50 basis points boosted share prices across the ...

LAVAL, QC / ACCESSWIRE / September 11, 2024 / Bausch Health, Canada Inc., part of Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced the approval by Health Canada of PrCABTREOTM ...

The list of World's Most Trustworthy Companies recognizes companies in 23 different industries from 20 different countries. Being aware that trust can be evaluated from different angles, Newsweek ...

(Bloomberg) -- Bausch Health Cos. is working with Jefferies Financial Group to explore refinancing some of its debt to aid a long-planned spinoff of its stake in the eye-care company Bausch + Lomb, ...